iTeos Therapeutics, Inc.

NasdaqGM ITOS

iTeos Therapeutics, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2024: USD 54.57 M

iTeos Therapeutics, Inc. Total Non-Current Liabilities is USD 54.57 M for the quarter ending September 30, 2024, a 6.67% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

iTeos Therapeutics, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2023 was USD 51.16 M, a 2.64% change year over year.
iTeos Therapeutics, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2022 was USD 49.84 M, a 514.44% change year over year.
iTeos Therapeutics, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2021 was USD 8.11 M.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

NasdaqGM: ITOS

iTeos Therapeutics, Inc.

CEO	Dr. Michel Detheux Ph.D.
IPO Date	July 24, 2020
Location	United States
Headquarters	321 Arsenal Street
Employees	157
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Key trends

Past 5 years